Has Edward Taylor, MD received payments from drug or device companies?

Yes. Drug and device makers reported $9,053 in general payments to Edward Taylor, MD across 644 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Edward Taylor, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Edward Taylor, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Edward Taylor, MD

Internal Medicine · Omaha, NENPI 1578674008

Payments from drug & device makers

$9,053in general payments, 2019–2025

Across 644 payments — averaging $14.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
Pfizer$855
Boehringer Ingelheim$679
Lilly USA, LLC$644
Novo Nordisk$526
GSK$511
plus $5K from 51 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	64	$1,058
Pfizer	73	$855
Boehringer Ingelheim	53	$679
Lilly USA, LLC	57	$644
Novo Nordisk	44	$526
GSK	54	$511
Amgen	42	$491
AstraZeneca(2 entities)	18	$458
Otsuka America Pharmaceutical, Inc.	24	$377
Sanofi-aventis U.S. LLC	22	$365
Sumitomo Pharma America, Inc.	17	$306
Amarin Pharma, Inc.	18	$272
Gilead	12	$208
Astellas Pharma US Inc	14	$203
Novartis	11	$165
Teva Pharmaceuticals USA, Inc.	9	$154
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	10	$149
Bayer	9	$147
Boston Scientific	6	$141
Biohaven Pharmaceuticals, Inc.	8	$117
E.r. Squibb & Sons, L.L.C.	7	$109
Johnson & Johnson	8	$105
Daiichi Sankyo Inc.	5	$77
Takeda Pharmaceuticals U.S.A., Inc.	6	$66
Abbott	4	$66
Pulmonx Corporation	2	$56
Kowa Pharmaceuticals America, Inc.	4	$48
Insulet Corporation	3	$42
Kyowa Kirin, Inc.	3	$40
Ardelyx, Inc.	2	$40
Radius Health, Inc.	2	$39
Genentech USA, Inc.	2	$34
Xeris Pharmaceuticals, Inc.	2	$33
Dexcom, Inc.	2	$33
Ultragenyx Pharmaceutical Inc.	2	$33
Ascensia Diabetes Care US Inc.	2	$32
Lundbeck LLC	2	$31
Merck	2	$31
Neurelis, Inc.	1	$26
Aimmune Therapeutics, Inc.	1	$23
Inspire Medical Systems, Inc.	1	$22
Dynavax Technologies Corporation	1	$20
Biohaven Pharmaceutical Holding Company Ltd.	1	$20
Sanofi Pasteur Inc.	1	$19
Axsome Therapeutics, Inc.	1	$17
Scilex Pharmaceuticals Inc.	1	$17
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	1	$17
Insmed, Inc.	1	$16
Bausch Health US, LLC	1	$14
Upsher-smith Laboratories LLC	1	$14
Esperion Therapeutics, Inc.	1	$14
Antares Pharma, Inc.	1	$14
Verona Pharma, Inc.	1	$14
Nestle Healthcare Nutrition Inc.	1	$13
Arbor Pharmaceuticals, Inc.	1	$12
Circassia Inc.	1	$12
Organon	1	$9

How this compares

$9,053 in reported general payments places this provider in the 90th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska →

Medicare billing

Part B allowed, 2024

$749,577

Medicare patients

882

Services billed

18,940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Omaha

Michael DunnOmaha$7.9M
Joel MichalskiOmaha$1.6M
Ariana BauerOmaha$1.5M
David CrockettOmaha$821K
Bryant EnglandOmaha$637K
Adam BurdorfOmaha$313K
Brian BoerOmaha$142K
David JasperOmaha$128K
Andrew RorieOmaha$61K
Mohamed AhmedOmaha$57K

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →